Another theory is that these drugs influence certain pathways in your brain and nervous system that also affect your digestive system
Currently, Survodutide is under development for the treatment of obesity (Phase III) and MASH (Phase II), with BI exclusively responsible for its global development and commercialization (Zealand retains co-promotion rights in Nordic countries)
No trial for plantar fasciitis
Its clinical development was discontinued, and it is sold only as a research chemical labeled for laboratory use
These peptides activate MRGPRX2, a mast-cell receptor that fires on positively charged, aromatic molecules and releases histamine into the tissue. Sodium and chloride ions screen the peptides positive charge, so the receptor sees less of it and the welt shrinks
To truly address this issue, expanding networks of participating clinics and increasing reimbursement amounts are crucial steps